Yali Dou, Ph.D.

Yali Dou, Ph.D

Professor, Pathology
Professor, Biological Chemistry

5215 Med Sci I
1301 Catherine St
Ann Arbor, MI  48109-5602
 

(734) 615-1315

Areas of Interest

Cell fate decisions are controlled by tissue-specific transcription factors acting in concert with epigenetic regulators such as enzymes that carry out histone post-translational modifications. Epigenetic dysregulation emerges as a key characteristic of human malignancies. The Dou lab seeks to determine the epigenetic basis of normal and aberrant embryonic and hematopoietic development. By comparing the ontogeny of gene regulatory networks in embryonic stem cells as well as leukemia stem cells, the lab aims to understand how lineage-specifying transcription factors, non-coding DNA regulatory regions and epigenetic modulating enzymes cooperate to maintain or reprogram stem cell characteristics, expand differentiation potentials, and perturb disease development. These studies promise to not only advance our understanding of the context-specific roles of epigenetic modulators in development and diseases, but also provide critical insights into designing novel target-based therapeutic strategies in cancer treatment and regenerative medicine.

Honors & Awards

Basic Science Research Award, University of Michigan Medical School, 2014
Scholar Award, Leukemia & Lymphoma Society, 2012
Innovative Research Grant, Stand Up To Cancer, 2011
Gertrude B. Elion Cancer Research Award, American Association for Cancer Research, 2010
Research Scholar Grant, American Cancer Society, 2010
Biological Sciences Scholar, University of Michigan, 2006

Published Articles or Reviews

Recent Publications

Histone Acetyltransferase MOF Blocks Acquisition of Quiescence in Ground-State ESCs through Activating Fatty Acid Oxidation.
Khoa LTP, Tsan YC, Mao F, Kremer DM, Sajjakulnukit P, Zhang L, Zhou B, Tong X, Bhanu NV, Choudhary C, Garcia BA, Yin L, Smith GD, Saunders TL, Bielas SL, Lyssiotis CA, Dou Y.
Cell Stem Cell. 2020, in press.

Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase.
Chern TR, Liu L, Petrunak E, Stuckey JA, Wang M, Bernard D, Zhou H, Lee S, Dou Y, Wang S.
ACS Med Chem Lett. 2020; 11: 1348–52.

Mutually suppressive roles of KMT2A and KDM5C in behaviour, neuronal structure, and histone H3K4 methylation.
Vallianatos CN, Raines B, Porter RS, Bonefas KM, Wu MC, Garay PM, Collette KM, Seo YA, Dou Y, Keegan CE, Tronson NC, Iwase S.
Commun Biol. 2020; 3: 278.

Insights on the regulation of the MLL/SET1 family histone methyltransferases.
Sha L, Ayoub A, Cho US, Dou Y.
Biochim Biophys Acta Gene Regul Mech. 2020; 1863: 194561.

Maintenance of neural stem cell positional identity by mixed-lineage leukemia 1.
Delgado RN, Mansky B, Ahanger SH, Lu C, Andersen RE, Dou Y, Alvarez-Buylla A, Lim DA.
Science. 2020; 368: 48–53.

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W.
J Clin Invest. 2020; 130: 2712–26.

Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Gibbons GS, Chakraborty A, Grigsby SM, Umeano AC, Liao C, Moukha-Chafiq O, Pathak V, Mathew B, Lee YT, Dou Y, Schürer SC, Reynolds RC, Snowden TS, Nikolovska-Coleska Z.
Eur J Med Chem. 2020; 189: 112023.

p53 Integrates Temporal WDR5 Inputs during Neuroectoderm and Mesoderm Differentiation of Mouse Embryonic Stem Cells.
Li Q, Mao F, Zhou B, Huang Y, Zou Z, denDekker AD, Xu J, Hou S, Liu J, Dou Y, Rao RC.
Cell Rep. 2020; 30: 465–80.e6.

For a list of publications from Michigan Research Experts, click HERE